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Abstract 
Background: Pseudomonas aeruginosa is a common Gram-negative, rod-shaped bacterium that has a unique 
genome that allowed the bacteria to produce various enzymes and proteins. Azurin and arginine deiminase are 
low molecular weight proteins that produced by P. aeruginosa. These proteins can be used alone or in 
combination together in order to become effective in cancer therapy or inhibiting of metastasis. This study 
aimed to design, express and purify the Azurin and Arginine Deiminease recombinant fusion protein. 
Materials and Methods: The sequences of Azurin and arginine deiminase from P. aeruginosa were studied for 
synthesis in a pET28a vector. The recombinant plasmid was transfected into the E.coli BL-21 strain and 
expression was induced by isopropyl-β-D-thio galactopyranoside (IPTG). The fusion protein expression was 
evaluated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Purification of the 
recombinant product was performed by the Ni-NTA chromatography column, obtained product analysis with 
SDS-PAGE and Western blot technique. 
Results: Cloning was confirmed by observing bands from the enzyme digestion. The protein band with a 
molecular weight of 65 kDa on the SDS-PAGE gel was an indication of the correct expression of the protein. 
The single-band of this recombinant protein was confirmed by the western blot technique. 
Conclusion: In this study, due to the successful production of arginine deiminase-azurin fusion protein, and 
considering the separate anti-cancer properties of these compounds, which have been reported in previous 
studies, it is suggested that immunological assessments and effects of this fusion protein in different cancerous 
cell line be investigated. 
Keywords: Pseudomonas aeruginosa, Azurin, Arginine deiminase, Fusion protein  
 
*Corresponding Author: Bahareh Hajikhani, Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical 
Sciences, Tehran, Iran. Tel:  (+98) 21-23872556. Email: b.hajikhani@gmail.com 
 
Please cite this article as: Hadi M, Ghazi M, Saffarian P, Hajikhani B. Design and Production of Arginine Deiminase-Azurin 
Recombinant Fusion Protein from Pseudomonas aeruginosa and its Confirmation by Western Blot. Novel Biomed. 2020;8(2):63-70. 
 
Introduction 
Pseudomonas aeruginosa is a gram-negative, rod-
shaped bacterium which is one of the main causes of 
nosocomial infections, especially in cystic fibrosis 
patients, burns, and people with immune 
deficiency1,2. The variation of 
P. aeruginosa pathogenicity indicates that this 
bacterium has a unique genome and has a tremendous 
enzymatic power, which allows the bacteria to survive 
in different conditions3. 10% of the genome of this 
bacterium is organized in pathogenicity islands, which 
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provides the most pathogenic variation for 
P. aeruginosa 4. P. aeruginosa expresses a variety of 
cellular products, such as adhesins, proteases, 
phospholipase, exotoxins, which are related to its 
pathogenesis5. Azurin and Arginine deiminase as two 
proteins produced by P. aeruginosa play a major role 
in pathogenesis of this bacterium6,7. 
Azurin is a low molecular weight protein (128 amino 
acids -14 kDa) and a member of the cupredoxin 
family produced by P. aeruginosa 7. This protein has 
an effect on the electron transfer cycle during the 
respiration of germs and carries an electron in the 
respiration process8. Azurin has anti-cancer and 
antiviral properties9. 
Arginine deiminase widely used as a therapeutic 
agent for the treatment of arginine-auxotrophic 
tumors, such as hepatocellular carcinomas and 
melanomas10-13. Arginine deiminase extracted from 
P. aeruginosa is called Pa-ADI14. Active Arginine 
deiminase as a tetramer protein of about 46 
kilodaltons per monomer and catalyzes irreversible 
hydrolysis of L-arginine to Citrulline and 
Ammonium15,16. 
Pseudomonas proteins and genes are used to design 
and produce fusion protein for pharmaceutical and 
therapeutic purposes17-20. The fusion protein made in 
the laboratory by combining different genes or parts 
of the genes from the same or different organisms. 
The produced fusion protein may yield different 
functions derived from each of its components21. 
Construction of recombinant fusion proteins is 
accepted as a means to increase the expression of 
soluble proteins and facilitating protein 
purification22.  
Considering the ability of this bacterium, like its 
different protein production, which is used in 
vaccination strategies, its pathogenesis antibiotic 
resistance which have been considered during 
treatment; in this study, we designed and produced 
azurin and arginine deiminase fusion protein from P. 
aeruginosa for the first time and provided an 
opportunity for further research. 
Methods 
Bacterial strains and materials: E. coli DH5α 
and E. coli BL21 (DE3) were purchased from Pasteur 
Institute of Iran, Tehran, Iran for cloning and 
expression experiments, respectively. Ni-NTA 
purification resin purchased from QiagenTM, South 
Korea. The NcoI and HindIII restriction enzymes were 
obtained from TAKARA, Japan. Kanamycin and Anti-
poly-histidine antibody-HRP was purchased from 
Sigma-Aldrich, Germany. 
Bioinformatics studies: To construct the fusion 
protein, azu and arcA gene sequences were obtained 
from NCBI website and the (GlyGlyGlySer) x2 
sequence were used as a linker between two proteins; 
after codon optimization spatial shape, half-life and 
instability index of the fusion protein were determined 
using Raptor X Binding and Prot Param online 
software. The gene fragment was ordered to Biomatik 
Company (Canada) for synthesis in the pET-28a 
vector between NcoI and HindIII restriction enzyme 
sites. 
Transformation of the recombinant plasmid: The 
recombinant pET28a-arcA-azu plasmid was 
transformed into E.coli DH5α competent cells by 
thermal shock method. Amplified plasmids were 
extracted using the plasmid extraction kit (Bioneer, 
Korea). The presence of arcA-azu gene sequence in 
the plasmid was confirmed by enzymatic double 
digestion; Digestion of the produced plasmids by NcoI 
/ Hind III was carried out at 37ºC for 1.5 h to release 
the gene fragment and was detected by gel 
electrophoresis. 
Expression and purification of the fusion protein: 
Induction and expression of the recombinant arcA-
azu gene were carried out in E.coli BL21 (DE3) 
competent cells. A single colony from BL21 harboring 
the construct was inoculated in 1 Liter of Luria-
Bertani broth (LB) culture containing kanamycin at 
final concentration 100 µg/ml. The culture was used 
for expression and when the optical density (OD at 
600 nm) reached 0.6 nm, induction performed with 0.5 
mM of IPTG at 37°C for 3 hours. 
Bacteria were precipitated by centrifugation at 12000 
rpm for 20 min at 4ºC and resuspended in a lysis 
buffer (50 mM NaH2PO4, 0.3 M NaCl, 8 M urea, pH 
8.0). After the cells were lysed, the suspension was 
sonicated (5 cycles of 60 seconds pulses and 1-minute 
intervals) on ice and debris was removed by 
centrifugation at 14000 rpm for 12 min. 
Ni-NTA affinity chromatography was used for the 
purification of the fusion protein. The supernatant of 
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the cell lysate was passed through the nickel–NTA 
column and the column was washed with decreasing 
urea concentration (from 0 to 8 M) and then the 
column was eluted with increasing imidazole 
concentration (concentration gradient of imidazole 
150-500 mM). The expressed and purified fusion 
protein were analyzed by 12.5% SDS–PAGE and 
stained with the Coomassie Brilliant Blue R-250, was 
examined. 
Antigenicity of the fusion protein: Antigenicity of 
the fusion protein was evaluated using western blot 
analysis. Western blotting was performed on 12.5% 
SDS-PAGE. The protein bands in SDS-PAGE were 
transmitted by electrical force to the nitrocellulose 
membrane (0.45 μm) using standard procedure. The 
nitrocellulose membrane was blocked with Tris-
buffered saline (TBS) – skim milk 1 % for 2 h. 
Membrane was washed in Tris-Buffered Saline 
Tween-20 (TBS-T) for 3 times. According to the 
design of the histidine sequence at the end of the 
fusion protein, the Anti-poly histidine HRP antibody 
(Sigma) was used at 1 to 1000 dilutions in TBS-T. 
Finally, the nitrocellulose membrane was placed in 
0.5 mg/ml 3, 3’- diaminobenzidine (DAB) solution 
containing 0.1% hydrogen peroxide, for 30 minutes, 
and the appearance of the desired protein band was 
investigated. 
Results 
The prediction of the fusion protein showed that the 
linker could keep two proteins apart (Fig. 1). 
Biochemical analysis of fusion protein showed that 
the molecular weight of the fusion protein was 65038 
Dalton and the isoelectric point was 5.84. The 
aliphatic index of the fusion protein was 86/26 and the 
instability index was 35/86. The instability index 
indicates the sustainability of recombinant protein in 
such a way proteins with an index of less than 40 are 
categorized in Stable proteins. 
Transformation of the recombinant plasmid: To 
confirm the transformation, cutting 
with NcoI and HindIII restriction enzymes with one 
cut site on the vector were used. The recombinant gene 
was detected at 1745 bp in the lower region of the 
linearized plasmid on the agarose gel 1% (Fig. 2). 
Expression and purification of the fusion protein: 
The best level of expression was determined in IPTG 
0.5 mM, temperature 37°C and 3 h post-induction 
incubation time. To evaluate the protein expression, 
The IPTG induced samples, as well as non-induced 
samples as the negative control, were analyzed on 
SDS-PAGE. The fusion protein band of the 
recombinant arginine deiminase-azurin protein was 
obtained after staining with Coomassie Brilliant Blue 
250-R (Fig. 3). 
The molecular weight of the recombinant fusion 
protein was 65.05 kDa. The presence of the induced 
band in the range of 65 kDa of protein corresponded 
with the expected molecular weight. 
The existence of the Poly-histidine sequence at the end 
of the protein led to the use of a nickel affinity 
chromatography column to purify the protein. The 
expressed protein was mainly accumulated as 
inclusion bodies which purified by Ni2+ affinity 
chromatography under modified denaturing condition; 
for this purpose, the column was washed by using an 
 
 
Figure 1. Prediction of the spatial structure of the fusion protein. 
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elution gradient of 150 to 500 mM imidazole 
concentration and the purity of the protein was 
evaluated by SDS-PAGE (Fig. 4). 
Antigenicity of the fusion protein: Western blot 
was used to evaluate the antigenicity of the produced 
fusion protein. The purified protein was 
electrophoresed in the SDS-PAGE gel (Fig.5 A), the 
bands transferred to nitrocellulose paper. A brown 
strip consistent with the location of the recombinant 
protein appeared on nitrocellulose membrane that 
confirmed the fusion protein reaction with antibodies 
(Fig.5 B). 
Discussion 
The fusion protein is a protein made from hybrid 
genes, which is created by joining two or more 
different genes. Studies showed that the obtained 
fusion protein may yield many distinct functions 
derived from each of its molecular components21. As 
a result, production of fusion protein production is 
very cost-effective compared to natural proteins. 
Also, the use of fusion protein in comparison to the 
use of each protein alone increases the chance of 
receiving and producing fusion protein 
simultaneously in the desired host cell. 
In general, fusion protein has widespread use in 
biological research, such as protein purification23, 
cancer treatments24-26 and also use for enhancing the 
potency of cancer vaccine in the protein format26,27, 
which has made this compound an important 
category of biologically active substances28,29. 
P. aeruginosa is a Gram-negative opportunistic 
pathogen that known to secrete the protein called 
azurin as a weapon against invaders as cancers, 
parasites and viruses. The production of such proteins 
by pathogenic bacteria could provide views into how a 
pathogen uses mechanisms and proteins as responds to 
impede other intruders for its own survival. The 
pharmaceutical capacity of these molecules like azurin 
in the industry as next-generation therapeutics was 
found recently. Azurin (14 kDa, 128 amino acids) is a 
copper-containing single-domain protein with a rigid 
β-barrel structure, produced by P. aeruginosa. Azurin 
rely on the stability of the p53 protein capable to 
destroy tumor cells and inhibits the development of the 
cancer. In nucleus of azurin enhances the intracellular 
levels of p53 and Bax, and triggers the release of 
mitochondrial cytochrome C into the cytosol. Caspase 
cascade activates by this process and initiates the 
apoptotic process30. Over the years, many studies have 
been done on the synthesis and production of azurin 
and peptides and the fusion proteins31-33. In a study, 
the azurin-cytochrome P450 fusion protein was 
designed using azurin from P. aeruginosa and 
cytochrome P450 from Pseudomonas putida in pET-
21b vector and then transferred to E. coli BL21 and 
the fusion protein was obtained by chromatography 
column34. 
Arginine deiminase is another Pseudomonas protein 
 
 
Figure 2. Confirmation of recombinant plasmid containing 
arcA-azu  genes by double digestion; Lane 1: Molecular 
weight marker, Lane 2: Vector digested with NcoI 
and Hind III enzymes (recombinant gene with 1745 bp in the 




Figure 3. Evaluation of fusion protein expression in SDS-
PAGE gel; Lane 1: Protein Molecular Weight Marker, Lane 
2: Protein deposition of non-induced recombinant bacteria 
(Control Sample), Lane 3: Protein deposition of induced 
recombinant bacteria. 
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that encoded by the arcA gene35. This protein 
catalyzes hydrolysis of L-arginine to Citrulline and 
Ammonium36. Many studies have been done on the 
production of fusion/recombinant arginine-deiminase 
proteins and evaluated its effects37-40. Production of a 
fusion protein, arginine deiminase linked to albumin, 
along with one or more linker molecules, is one of 
the recent studies. The results suggest that this 
combination may be used to treat cancer and 
Arginine-related diseases in humans and animals, 
and also as an ingredient in a test kit for the 
identification of arginine41. 
According to different studies in the field of synthesis, 
cloning and expression of the azurin and arginine 
deiminase separately, and the effects of these proteins 
in the therapeutic and diagnostic fields, we decided to 
produce the azurin and arginine deiminase proteins 
from P. aeruginosa as a single recombinant fusion 
protein. 
Fusion protein and peptide expression in E. coli are 
confirmed previously. This bacterium efficiently can 
produce sufficient quantities of protein. Different 
items should be optimized like the host strain, the 
chosen vector, growth medium and temperature42. 
 
 
Figure 4. Evaluation of purity of fusion protein in the SDS-PAGE gel; Lane 1: Protein Molecular Weight Marker, Lane 2: Sample rinsing 




Figure 5. A: Fusion Protein on SDS -PAGE Gel Western Blot; Lane 1: Protein Molecular Weight Marker, Lane 2: Protein Deposition of 
Induced Recombinant Bacteria, Lane 3: Protein Purified from Recombinant Bacteria. B: Evaluation of antigenicity of the fusion protein 
with western blotting test; Lane 1: Protein Molecular Weight Marker, Lane 2: Protein Deposition of Induced Recombinant Bacteria, Lane 
3: Protein Purified from Recombinant Bacteria. 
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In this study, we presented the successful generation 
and high expression of fusion protein. Cloning and 
expression was performed in pET28a system under 
IPTG inducible T7 powerful promoter. The pET28a 
system is one the most common and suitable systems 
for cloning and expression of recombinant proteins. 
On the other hand, in order to obtain high level 
expression of fusion proteins, E. coli BL21 (DE3) 
was used as an expressed host. E. coli BL21 due to 
its well-known genetics, rapid and inexpensive 
cultivation is one of the most powerful and diverse 
expression systems. 
Arginine deiminase-azurin fusion protein was 
expressed in BL21 cells both the concentration of 
inducer and time of incubation have effect on the 
expression and production of protein. According to 
bioinformatics findings, this fusion protein is a stable 
protein and it can withstand long incubation time. 
Together with the incubation time, the temperature at 
which cells are grown is important. The 
concentration of IPTG and incubation time was 
optimum at 0.5 mM and 3 hours respectively, and 
good expression was observed in 37 temperature. 
Accuracy in recombinant constructs containing arcA-
azu with enzymatic double digestion was confirmed. 
Regards to SDS-PAGE results, recombinant proteins 
are significantly expressed in cell lysis compared to 
non-inducible samples. Additionally, we used the C-
terminal His tag on the pET28a vector to identify the 
protein in Western blotting and purify the fusion 
proteins by Ni-NTA affinity column. Studies have 
shown that the resin-nickel agarose system with 
high-affinity and selective used to fusion proteins 
that tagged with six histidine residues43. The 
procedure for producing fusion protein is quite 
convenient and efficient and would allow a 
laboratory to produce large amounts of fusion 
protein. 
The molecular weight of the azurin and arginine 
deiminase proteins is 62.5 kDa, which together with 
the linker protein and added sequences, the weight of 
the synthesized fusion protein reach up to 65.05 kDa. 
The presence of the induced band in the range of 65 
kDa of protein corresponded with the expected 
molecular weight. Therefore, results showed that the 
combination of a fusion protein containing azurin 
and arginine deiminase has been properly prepared 
and purified; and Western stain testing indicated the 
reactivity of this fusion protein by the Anti-poly 
histidine HRP antibody. 
Conclusion 
In conclusion, our data showed that the arcA-azu 
fusion gene can be expressed by pET28a vector in 
E.coli and we have successfully produced the 
recombinant arginine deiminase-azurin fusion protein 
with the presented procedure for preparation of large 
quantity of fusion protein for structure function 
studies. According to our data, further investigation 
could be on evaluation of the anti-cancer properties of 
this fusion protein and its clinical potential in therapy. 
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